DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Phase 3

Recruiting

Conditions: Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: Tarlatamab
Drug: Placebo

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-08

Lead Sponsor: Amgen

Target Recruit Count: 400

Registration Number: NCT06117774

Locations: 🇬🇷
European Interbalkan Medical Center, Thessaloniki, Greece
🇹🇷
Marmara Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey
🇪🇸
Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 188 locations

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Phase 3

Recruiting

Conditions: Sjogren's Syndrome

Interventions: Drug: Dazodalibep
Drug: Placebo

First Posted Date: 2023-10-27

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 621

Registration Number: NCT06104124

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸
Arizona Research Clinic PLLC, Chandler, Arizona, United States
🇺🇸
Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln, Flagstaff, Arizona, United States

and more 243 locations

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Phase 4

Recruiting

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: Avacopan
Drug: Placebo
Drug: Standard of Care

First Posted Date: 2023-10-10

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 300

Registration Number: NCT06072482

Locations: 🇺🇸
Orthopedic Physicians Alaska, Anchorage, Alaska, United States
🇺🇸
Scottsdale Healthcare at Shea - HonorHealth, Scottsdale, Arizona, United States
🇺🇸
Southwest Kidney Institute, Surprise, Arizona, United States

and more 35 locations

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Conditions: Small Cell Lung Cancer

First Posted Date: 2023-10-03

Last Posted Date: 2025-03-10

Lead Sponsor: Amgen

Registration Number: NCT06064500

Locations: 🇮🇱
Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 20 locations

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Phase 2

Recruiting

Conditions: Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
B Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: Blinatumomab

First Posted Date: 2023-09-26

Last Posted Date: 2025-03-07

Lead Sponsor: Amgen

Target Recruit Count: 18

Registration Number: NCT06054113

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Childrens Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Children's Hospital of Soochow University, Suzhou, Jiangsu, China

and more 2 locations

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3

Recruiting

Conditions: Melanoma

Interventions: Drug: ABP 206
Drug: Nivolumab

First Posted Date: 2023-09-26

Last Posted Date: 2025-05-14

Lead Sponsor: Amgen

Target Recruit Count: 620

Registration Number: NCT06054555

Locations: 🇮🇹
IRCCS Ca'Granda Maggiore Policlinic, Milano, Italy
🇮🇹
AOU Careggi, Firenze, Italy
🇺🇸
Cancer and Blood Specialty clinic, Long Beach, California, United States

and more 167 locations

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Avacopan

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Amgen

Target Recruit Count: 24

Registration Number: NCT06004934

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Hialeah, Florida, United States

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Phase 1

Completed

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: CCX168
Drug: Midazolam
Drug: Rifampicin
Drug: Celecoxib
Drug: Itraconazole

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT06004947

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

Phase 1

Completed

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: [14C]CCX168

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Amgen

Target Recruit Count: 6

Registration Number: NCT06004960

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ABP 501
Drug: Adalimumab

First Posted Date: 2023-08-16

Last Posted Date: 2023-08-16

Lead Sponsor: Amgen

Target Recruit Count: 179

Registration Number: NCT05995691

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy